Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Other financing activities: 2012-2018

  • Enanta Pharmaceuticals' Other financing activities was N/A to -$5.5 million in Q2 2018 from the same period last year, while for Jun 2018 it was -$3.5 million, marking a year-over-year change of. This contributed to the annual value of $325,000 for FY2023, which is N/A change from last year.
  • As of Q2 2018, Enanta Pharmaceuticals' Other financing activities stood at -$5.5 million, which was down 346.93% from $2.2 million recorded in Q1 2018.
  • Enanta Pharmaceuticals' Other financing activities' 5-year high stood at $2.2 million during Q1 2018, with a 5-year trough of -$5.5 million in Q2 2018.
  • For the 3-year period, Enanta Pharmaceuticals' Other financing activities averaged around -$364,200, with its median value being -$2,000 (2016).
  • Per our database at Business Quant, Enanta Pharmaceuticals' Other financing activities crashed by 160.00% in 2015 and then skyrocketed by 1,767.65% in 2016.
  • Enanta Pharmaceuticals' Other financing activities (Quarterly) stood at $1.9 million in 2014, then slumped by 160.00% to -$3,000 in 2015, then surged by 33.33% to -$2,000 in 2016, then reached -$245,000 in 2017, then reached -$5.5 million in 2018.
  • Its Other financing activities was -$5.5 million in Q2 2018, compared to $2.2 million in Q1 2018 and -$245,000 in Q4 2017.